Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

Circulation. 2002 Jul 16;106(3):379-85. doi: 10.1161/01.cir.0000019581.22812.b2.

Authors

Martin J Quinn¹, Edward F Plow, Eric J Topol

Affiliation

¹ Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

PMID: 12119257
DOI: 10.1161/01.cir.0000019581.22812.b2

No abstract available

MeSH terms

Acute Disease
Administration, Oral
Blood Platelets / drug effects
CD40 Ligand / physiology
Coronary Disease / drug therapy*
Coronary Disease / mortality
Humans
Inflammation / etiology
Infusions, Intravenous
Models, Cardiovascular
Myocardial Ischemia / prevention & control
Myocardial Revascularization
Platelet Aggregation Inhibitors / adverse effects*
Platelet Aggregation Inhibitors / pharmacology
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
Randomized Controlled Trials as Topic
Syndrome
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
CD40 Ligand